'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA
RBC Capital Reiterates Sector Perform on Moderna, Maintains $75 Price Target
Moderna Analyst Ratings
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $75
RBC Capital analyst Luca Issi maintains $Moderna(MRNA.US)$ with a hold rating, and adjusts the target price from $90 to $75.According to TipRanks data, the analyst has a success rate of 22.6% and a
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Moderna’s updated Covid-19 vaccine has been approved by the Canadian government.
Biotechnology company Moderna (MRNA.US) announced that after the United States, the Canadian government has approved its updated Covid-19 vaccine. The stock price rose 4.5% to $72.28 on Tuesday afternoon.
Equities Mixed Intraday as Traders Weigh Macro Data, Await Fed Decision
Sector Update: Health Care Stocks Decline in Afternoon Trading
Sector Update: Health Care
Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
Moderna Up Nearly 6%, Best Performer In The S&P 500 And The Nasdaq 100 So Far Today -- Data Talk
Express News | Moderna Shares up 6.7%
Moderna Shares Are Trading Higher Following Reports Suggesting That the Company Received Health Canada Approval for an Updated Covid-19 Vaccine.
Express News | Moderna: Will Promptly Begin Delivery of Updated Covid-19 Vaccines to Public Health Agency of Canada
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older